VJHemOnc Podcast
The AML Sessions: Venetoclax-based regimens
Nov 12, 2020
Naval Daver from MD Anderson Cancer Center leads an exciting discussion on the latest updates in the use of venetoclax-based regimens for the treatment of AML. Topics include the potential of azocididine and Venetoclax combination as a new standard of care, safety and feasibility of combination treatments, comparing regimens for AML patients, the dilemma of induction therapy, and ongoing studies and future directions in hematology.
25:43
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The combination of azacitidine and Venetoclax shows improved overall survival and could become a new standard of care for older, unfit AML patients.
- Combining Venetoclax with IDH inhibitors, flip three inhibitors, RAS inhibitors, and immunotherapy agents shows promising response rates in AML treatment.
Deep dives
Venetoclax and azacitidine combination improves overall survival in AML patients
The VLAA study, a confirmatory phase three study, showed that the combination of azacitidine and Venetoclax led to an improvement in overall survival in acute myeloid leukemia (AML) patients. The study, which included over 430 patients, demonstrated improved complete remission rates and composite remission rates compared to azacitidine alone. The combination also resulted in an extended median survival, making it a potential new standard of care for older, unfit AML patients. Safety concerns were addressed through monitoring, with no significant tumor lysis syndrome observed. The milder suppression associated with Venetoclax was manageable with appropriate management tools.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
